End-of-day quote
Korea S.E.
03:30:00 14/05/2024 am IST
5-day change
1st Jan Change
6,520
KRW
-0.31%
-5.78%
-25.74%
INtRON Biotechnology, Inc.'s Equity Buyback announced on December 2, 2022, has expired with 324,118 shares, representing 0.97% for KRW 2,997.54 million.
The company expired its plan on August 3, 2023.
INtRON Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
13/03
CI
Intron Biotechnology, Inc. Announces New Drug Part Secures A Potent Anti-Cancer Candidate, PHAGERIA®, with Broad Antimicrobial Activity Against ETBF (Enterotoxigenic B. Fragilis), A Harmful Microbe Associated with Colorectal Cancer
15/02
CI
INtRON Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
14/11
CI
Basilea Pharmaceutica Signs Evaluation License, Option Deal With Korea's iNtRON
31/23/31
MT
INtRON Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
11/23/11
CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on December 2, 2022.
03/23/03
CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on December 2, 2022.
03/23/03
CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on December 2, 2022.
03/23/03
CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on September 20, 2022.
03/23/03
CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on September 20, 2022.
03/23/03
CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on September 20, 2022.
03/23/03
CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on December 2, 2022.
03/23/03
CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on September 20, 2022.
03/23/03
CI
INtRON Biotechnology, Inc.'s Equity Buyback announced on December 2, 2022, has expired with 324,118 shares, representing 0.97% for KRW 2,997.54 million.
03/23/03
CI
INtRON Biotechnology, Inc.'s Equity Buyback announced on December 2, 2022, has expired with
03/23/03
CI
INtRON Biotechnology, Inc.'s Equity Buyback announced on September 20, 2022, has expired with 294,186 shares, representing 0.87% for KRW 2,998.6 million.
03/23/03
CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on July 5, 2022.
06/23/06
CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on July 5, 2022.
06/23/06
CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on July 5, 2022.
06/23/06
CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on July 5, 2022.
06/23/06
CI
INtRON Biotechnology, Inc.'s Equity Buyback announced on July 5, 2022, has expired with 274,732 shares, representing 0.81% for KRW 2,997.69 million.
05/23/05
CI
INtRON Biotechnology Identifies Prophage and Jamphage in the Pancreatic Cancer Related Microbiome
30/23/30
CI
INtRON Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
15/23/15
CI
INtRON Biotechnology, Inc. Confirms Cancer-Controlling Effect of Phageria Drug Candidate in the Organoid Model
04/23/04
CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on December 2, 2022.
06/23/06
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
iNtRON Biotechnology, Inc. is a Korea-based company principally engaged in the biotechnology industry. The Company operates its business through two main divisions: genetic reagent division and molecular diagnostics division. Its genetic reagent division is involved in the research and development of reagents, which are under the brand names of Maxime and pLUG for life science research. Its molecular diagnostics division is engaged in the development and production of nucleic acid tester for infectious diseases. It also engages in the operation of veterinary antibiotic alternative business and new biopharmaceuticals development business. The Company distributes its products within domestic market and to overseas markets.
More about the company
1st Jan change
Capi.
-25.74% 16Cr +7.42% 11TCr +11.24% 11TCr -12.68% 2.22TCr +0.44% 2.13TCr -4.18% 1.9TCr -37.85% 1.85TCr -8.68% 1.68TCr +37.39% 1.25TCr -23.89% 808.97Cr
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1